​

Brainstorm Cell Therapeutics Ownership | Who Owns Brainstorm Cell Therapeutics?

OverviewRevenueFinancialsChartTranscripts

Brainstorm Cell Therapeutics Ownership Summary

Brainstorm Cell Therapeutics is owned by 0.92% institutional investors, 20.84% insiders, and 78.24% retail investors. Blackrock is the largest institutional shareholder, holding 0.60% of BCLI shares. Vanguard US Total Market Shares ETF is the top mutual fund, with 1.33% of its assets in Brainstorm Cell Therapeutics shares.

BCLI Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockBrainstorm Cell Therapeutics0.92%20.84%78.24%
SectorHealthcare Stocks 57.39%9.93%32.68%
IndustryBiotech Stocks 68.48%9.65%21.87%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock386.41K0.60%$130.80K
Liberty wealth management22.67K0.43%$51.45K
Weaver consulting group15.62K0.29%$35.46K
Advisor group10.52K0.20%$2.42K
Northern trust112.36K0.17%$38.03K
Raymond james & associates111.28K0.17%$37.67K
Virtu financial49.59K0.08%$17.00K
Morgan stanley36.98K0.06%$12.52K
Lpl financial10.05K0.02%$3.40K
Citadel advisors7.20K0.01%$2.44K

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Weaver consulting group15.62K0.01%$35.46K
Liberty wealth management22.67K0.01%$51.45K
Virtu financial49.59K0.00%$17.00K
Institutional & family asset management6.00K0.00%$2.03K
Gsa capital partners llp---
Blackrock386.41K-$130.80K
Geode capital management---
Two sigma securities---
St germain d j---
Tower research capital llc (trc)---

Top Buyers

HolderShares% AssetsChange
Northern trust112.36K-57.57K
Virtu financial49.59K0.00%49.59K
Lpl financial10.05K-10.05K
Citadel advisors7.20K-6.40K
Simplex trading5.50K-1.47K

Top Sellers

HolderShares% AssetsChange
Armistice capital---6.90M
Vanguard group---1.51M
Geode capital management---682.82K
Blackrock funding, inc. /de---377.61K
Liberty wealth management22.67K0.01%-317.48K

New Positions

HolderShares% AssetsChangeValue
Lpl financial10.05K-10.05K$3.40K

Sold Out

HolderChange
Mark sheptoff financial planning-100.00
Corecap advisors-133.00
Northwestern mutual wealth management-161.00
Jpmorgan chase-175.00
Westside investment management-200.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 20244-89.19%48,928-99.55%-0.40%1-90.00%2-77.78%
Sep 30, 202437-26.00%10,822,353-10.37%154.37%10-52.38%9-
Jun 30, 2024504.17%12,075,121210.89%1851.82%2175.00%9-18.18%
Mar 31, 202448-4.00%3,884,1112.17%57.70%12-29.41%11-8.33%
Dec 31, 202350-12.28%3,801,493-17.96%88.05%17-32.00%12-

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Vanguard US Total Market Shares ETF1.06M1.33%-2.00
Fidelity Extended Market Index27.43K0.48%-175.00
Vanguard Institutional Extnd Mkt Idx Tr26.73K0.47%-
Vanguard Total Stock Mkt Idx Inv22.14K0.39%-28.58K
Fidelity Total Market Index9.56K0.17%-
Fidelity Series Total Market Index6.85K0.12%-
NT Ext Equity Mkt Idx Fd - L5.32K0.10%-
Northern Trust Extended Eq Market Idx5.32K0.09%4.96K
BlackRock Extended Equity Market K62.75K0.08%-27.00
Extended Equity Market Fund K4.14K0.08%13.00

Recent Insider Transactions

DateNameRoleActivityValue
Oct 01, 2024Lebovits Chaim President & CEOBuy$6.29K
Sep 30, 2024Lebovits Chaim President & CEOBuy$5.02K
May 28, 2024Lebovits Chaim President & CEOBuy$7.77K
May 21, 2024Lebovits Chaim President & CEOBuy$14.47K
May 22, 2024Lebovits Chaim President & CEOBuy$16.00K

Insider Transactions Trends

DateBuySell
2025 Q1--
2024 Q41-
2024 Q311
2024 Q211-
2024 Q1--

BCLI Ownership FAQ

Who Owns Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics shareholders are primarily institutional investors at 0.92%, followed by 20.84% insiders and 78.24% retail investors. The average institutional ownership in Brainstorm Cell Therapeutics's industry, Biotech Stocks , is 68.48%, which Brainstorm Cell Therapeutics falls below.

Who owns the most shares of Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics’s largest shareholders are Blackrock (386.41K shares, 0.60%), Liberty wealth management (22.67K shares, 0.43%), and Weaver consulting group (15.62K shares, 0.29%). Together, they hold 1.32% of Brainstorm Cell Therapeutics’s total shares outstanding.

Does Blackrock own Brainstorm Cell Therapeutics?

Yes, BlackRock owns 0.60% of Brainstorm Cell Therapeutics, totaling 386.41K shares as of Jun 2024. This represents 0% of BlackRock's total assets, with a market value of 130.8K$. In the last quarter, BlackRock decreased its holdings by -103K shares, a -21.03% change.

Who is Brainstorm Cell Therapeutics’s biggest shareholder by percentage of total assets invested?

Weaver consulting group is Brainstorm Cell Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.01% of its assets in 15.62K Brainstorm Cell Therapeutics shares, valued at 35.46K$.

Who is the top mutual fund holder of Brainstorm Cell Therapeutics shares?

Vanguard US Total Market Shares ETF is the top mutual fund holder of Brainstorm Cell Therapeutics shares, with 1.33% of its total shares outstanding invested in 1.06M Brainstorm Cell Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools